There are also medical conditions where weight-loss drugs would not be recommended, including a history of medullary thyroid cancer, pancreatitis, gastroparesis, or a family history of MEN2 (multiple endocrine neoplasia syndrome type 2
So, if pharmacies were to customize the product which is really how compounding is supposed to be done they can continue compounding, even though the drug is not in shortage
About 8 states have stricter telehealth rules that effectively ban remote controlled-substance prescribing for weight loss, even with the federal waiver: For GLP-1s (non-controlled) , telehealth is generally allowed in all states as long as you meet the standard of care (comprehensive evaluation, follow-up monitoring)
It is classified as Category 2 on the FDA list of bulk drug substances presenting significant safety risks for compounding
These mechanisms collectively improve glucose control, reduce appetite, and promote significant and clinically meaningful weight loss
All factors were independently scored by two observers on a scale of 04: 0 = none
